Measurement of estrogen effect on bone turnover by 2H2O labeling.
Estrogen loss has been known to increase bone turnover through accelerated bone resorption coupled by increased bone formation. In the present study, we measured estrogen effect on bone turnover by incorporation of 2H from 2H2O into amino acids. At 6 weeks of age, rats were either sham-operated (sham) or ovariectomized (ovx). Two weeks after surgery, 17beta-estradiol (est) was implanted subcutaneously to ovx rats. At 9 weeks of age, 2H2O labeling started by administration of 4% 2H2O to rats for 4 or 7 weeks in drinking water after a single intraperitonial bolus injection with 99.9% 2H2O. Body 2H2O enrichments were stable at approximately 3.0% over labeling period. Fractional replacements (f) of the midshaft femur were higher in the sham group (40.36 +/- 4.89% vs 42.47 +/- 11.22%) than the ovx (28.57 +/- 9.67% vs 37.47 +/- 8.34%) and est (26.57 +/- 4.00% vs 30.35 +/- 5.34%) groups 4 and 7 weeks after labeling, respectively. Ovariectomy-induced bone loss was observed in the trabecular bone along with a significantly increased number of osteoclasts, all of which were normalized after estradiol treatment. Taken together, our results indicate that estrogen deficiency significantly reduces the proportion of newly synthesized bone matrix as well as the total amount of bone matrix. The reduced portion of new matrix in ovx rats, presumably caused by activated osteoclastic degradation, was compensated rapidly with time. In addition, estradiol treatment protected the bone matrix by decreasing bone turnover rate.
Jeong
K S
KS
Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University, South Korea.
Lee
J
J
Jeong
W
W
Noh
D H
DH
Do
S H
SH
Kim
Y K
YK
D000409:Alanine / Q000378:metabolism; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D001857:Bone Matrix / Q000187:drug effects / Q000378:metabolism; D016723:Bone Remodeling / Q000187:drug effects*; D017666:Deuterium Oxide / Q000493:pharmacokinetics*; D004343:Drug Implants; D004958:Estradiol / Q000494:pharmacology*; D016326:Extracellular Matrix Proteins / Q000378:metabolism; D005260:Female; D005269:Femur / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D010010:Osteoclasts / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D010052:Ovariectomy; D051381:Rats; D017207:Rats, Sprague-Dawley
D004343:Drug Implants; D016326:Extracellular Matrix Proteins; D004958:Estradiol; D017666:Deuterium Oxide; D000409:Alanine